Adalimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Oxaliplatin
Platinum · Antineoplastic
PlatinumAntineoplastic
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
11 major
incl. contraindicated
PREGNANCY
Avoid - toxicity in animal studies
FDA category + note
Top interactionssee all 11 →
- AdalimumabSevereDatabaseDDInter
- AmiodaroneSevereDatabaseDDInter
- AmisulprideSevereDatabaseDDInter
- AnagrelideSevereDatabaseDDInter
Mechanism
Oxaliplatin is a third-generation platinum compound carrying a 1,2-diaminocyclohexane (DACH) carrier ligand. Like cisplatin, it forms platinum-DNA adducts causing intrastrand cross-links, but the bulky DACH ligand produces adducts that are not recognized by the mismatch repair (MMR) system — making oxaliplatin effective against cisplatin-resistant tumors with MMR deficiency, particularly colorectal cancer. Its dose-limiting toxicity is a cumulative peripheral sensory neuropathy rather than the nephrotoxicity and ototoxicity seen with cisplatin.
Indications
Recurrent or metastatic squamous cell cancer of the head and neck (in combination with platinum-based chemotherapy)colorectal cancer (in combination with 5FU)gastric cancerColorectal cancerGastroesophageal cancersPancreatic cancers
Dosing
- Adult
- with paclitaxel for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents.…
Pharmacokinetics
Onset
not specified
Peak effect
not specified
Bioavailability
—
Protein binding
not specified
Metabolism
not specified
Excretion
—
Contraindications
- Pregnancy
- Breastfeeding
Side effects
Common
peripheral neuropathy (dose-limiting toxicity)acute peripheral neuropathy (triggered by exposure to cold liquids, manifests as paresthesias or dysesthesias in extremities, mouth, and throat)cumulative dose-related peripheral neuropathy (similar to cisplatin, with dysesthesias, ataxia, and numbness of the extremities)mild to moderate hematological toxicitynausea (well controlled with serotonin [5HT3] receptor antagonists)DiarrhoeaAcute allergic reactionsPeripheral neuropathy (sensory paresthesias)Acute neuropathy triggered by cold
Serious
- Pulmonary hypertension
- Renal thrombotic microangiopathy
- Necrotising fasciitis (usually secondary to wound healing complications, gastro-intestinal perforation or fistula formation)
- Congestive heart failure
- Posterior reversible encephalopathy syndrome (presenting as seizures, headache, altered mental status, visual disturbance or cortical blindness, with or without hypertension)
- Osteonecrosis of the jaw
- leukemia (months to years after administration)
- pulmonary fibrosis (months to years after administration)
- acute allergic response (urticaria, hypotension, bronchoconstriction)
- Myelosuppression
Pregnancy & lactation
Pregnancy
Avoid - toxicity in animal studies
Lactation
Manufacturer advises avoid breastfeeding during and for at least 6 months after treatment
Drug interactions
Amiodarone
Severe
Database
Drug interaction classified as: synergy.
Source: DDInter
Amisulpride
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Anagrelide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Arsenic Trioxide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Baricitinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Bedaquiline
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Bepridil
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cabozantinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Ceritinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Certolizumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
1 additional unreviewed or low-confidence interaction hidden because their provenance or source detail is insufficient.
Related guidelines
Ask House about Oxaliplatin
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: KD Tripathi 7e, Goodman & Gilman 14e, BNF·Updated: 2026-05-13